Nozin Nasal Sanitizer Programs Reduce MRSA Infections, Lower Healthcare Costs Say Hospital Clinicians


Hospitals achieved up to 98% decrease in MRSA superbug infection rates and $1.9 million in savings with programs using Nozin® Nasal Sanitizer® antiseptic on patients. Results reported at Association of Professionals in Infection Control (APIC) and Infectious Disease Society of America (IDSA IDWeek) annual conferences.


BETHESDA, Md., – Across the U.S., hundreds of hospitals are utilizing Nozin® Nasal Sanitizer® antiseptic to improve patient care and reduce healthcare costs. Five major hospitals presented clinical evidence of lower costs and reduced methicillin-resistant Staphylococcus aureus (MRSA) healthcare-associated infections (HAIs) after introducing  Nozin® Nasal Sanitizer® programs. The results were presented at APIC 2019 conference in Philadelphia and IDWeek 2019 annual conference in Washington, D. C.

The hospitals' improved outcomes included lower MRSA infection rates, decrease in patient isolation days and reduced use of contact precautions contributed to an estimated $1.9 million in savings for the facilities.

For detail on the hospital clinical outcomes please visit:

The successful clinical outcomes with Nozin programs are timely as the Centers for Disease Control and Prevention (CDC) is alerting hospitals to do more to stop the dangerous, antibiotic-resistant MRSA superbug as well as the methicillin susceptible Staph aureus (MSSA) strain. 30% of the general population carry Staph aureus in their nose. In 2019, the CDC reported 119,000 bloodstream Staph aureus HAI and 20,000 deaths in U.S. MRSA nasal colonization is the #1 risk factor for MRSA HAIs and 13% of ICU patients may have MRSA nasal carriage. The clinicians reported that Nozin programs reduce this risk without using antibiotics, contributing towards goals of antibiotic stewardship, a key CDC objective. 

Nozin programs help safely decrease the need for nasal screening for MRSA, isolation of patients and contact precautions (e.g. gowns and gloves).  While this resulted in substantial savings, the clinicians also noted improved quality of care along with higher patient and staff satisfaction.

Supporting Quotes from Hospital Clinicians

"We had some really amazing study results…so given our success, we're going to continue this [Nozin program].  I cannot imagine not doing it because you have the satisfaction of your staff, you decrease isolation fatigue and you bring back the focus of why we put patients on isolation precautions to begin with." Heather Stegmeier, RN, MSN, CIC, AdventHealth Wesley Chapel Hospital

"We've been able to really see the success of that [Nozin program] and had very good feedback from all the practitioners." Jacqueline Whitaker, RN, MS, CPHRM, CPHQ, CIC, FAPIC, Director of Infection Control, AdventHealth Tampa Bay Hospital

"These types of results are vital for any provider organization that seeks to thrive in this value-based health care environment that we live in today." Gwen Borlaug, MPH, CIC, FAPIC, Infection Prevention Consultant, Borlaug Infection

About Nozin

Nozin is the leading brand in nasal decolonization. Nozin programs from Global Life Technologies Corp. are empowering healthcare professionals in hundreds of hospitals. Designed to improve care, lower infection risk and reduce healthcare costs, these programs utilize Nozin® Nasal Sanitizer® antiseptic with clinically supported infection prevention solutions for healthcare facilities, their patients and the providers who care for them.

Note: Nozin® and Nasal Sanitizer® are registered trademarks of Global Life Technologies Corp. All other company and product names may be trademarks of their respective owners.


For more information, please visit:

Media Contact

Kevin Watson
(301) 337-2059

Health Professionals:
Request a comprehensive analysis of your colonization risk mitigation protocols today.

© 2004-2023 Global Life Technologies Corp. All rights reserved. All trademarks are property of their respective owners. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.